Pegfilgrastim: evidence in support of its use with cytotoxic chemotherapy.

about

Pegfilgrastim for PBSC mobilization and autologous haematopoietic SCT.

P2860

Q37421288-2909A269-80F2-4E18-B99A-CA05E5EE2DF5

P2860

Pegfilgrastim: evidence in support of its use with cytotoxic chemotherapy.

Item

http://www.wikidata.org/entity/Q36235531

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Pegfilgrastim: evidence in support of its use with cytotoxic chemotherapy.

@ast

Pegfilgrastim: evidence in support of its use with cytotoxic chemotherapy.

@en

type

Item

label

Pegfilgrastim: evidence in support of its use with cytotoxic chemotherapy.

@ast

Pegfilgrastim: evidence in support of its use with cytotoxic chemotherapy.

@en

prefLabel

Pegfilgrastim: evidence in support of its use with cytotoxic chemotherapy.

@ast

Pegfilgrastim: evidence in support of its use with cytotoxic chemotherapy.

@en

P1476

Pegfilgrastim: evidence in support of its use with cytotoxic chemotherapy.

@en

P2093

Michael D Green

http://www.w3.org/2001/XMLSchema#string

Raymond Ng

http://www.w3.org/2001/XMLSchema#string

P2860

Dose-response effect of adjuvant chemotherapy in breast cancer

Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Ran

2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.

First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.

Recombinant human granulocyte colony-stimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primates.

Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy.

Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.

Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.

Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer.

A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.

P304

585-590

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737140.5.4.585

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2005-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16111460

http://www.w3.org/2001/XMLSchema#string

Pegfilgrastim: evidence in support of its use with cytotoxic chemotherapy.

about

P2860

P2860

Pegfilgrastim: evidence in support of its use with cytotoxic chemotherapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698